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Abstract: Early formulation screening can alleviate development of advanced oral drug formulations, 
such as amorphous solid dispersions (ASDs). Traditionally, dissolution is used to predict ASD 
performance. Here, a high-throughput approach is described that simultaneously screens drug 
dissolution and permeation employing a two-compartment 96-well plate. Freeze-drying from 
hydro-alcoholic solutions was used to prepare amorphous formulations. The screening approach was 
tested on amorphous and crystalline tadalafil formulations with and without Soluplus®. The workflow 
consisted of: (1) dispersion of the formulations; (2) incubation within the two-compartment plate, 
where a dialysis membrane separated donor (dispersed formulation) and acceptor; (3) sampling 
(donor and acceptor), where donor samples were centrifuged to remove non-dissolved material; and 
(4) quantification by UHPLC-UV. To identify optimal screening conditions, the following parameters 
were varied: dispersion medium (buffer/biomimetic media), acceptor medium (buffer/surfactant 
solutions), and incubation time (1 ,3 , and 6 h). Surfactants (acceptor) increased tadalafil permeation. 
Biomimetic medium (donor) enhanced dissolution, but not permeation, except for freeze-dried 
tadalafil, for which the permeated amount increased. The predictiveness was evaluated by 
comparing dissolution-/permeation-results with in vivo bioavailability. In general, both dissolution 
and permeation reflected bioavailability, whereof the latter was a better predictor. High-throughput 
dissolution/permeation is regarded promising for formulation screening.
Keywords: solubility; dissolution; supersaturation; solubilization; permeability; biomimetic; sink;
high-throughput screening; amorphous solid dispersions
1. Introduction
Drug candidates selected by drug discovery approaches are advanced to preclinical and 
clinical development by formulation efforts. For new chemical entities (NCEs), where sufficient 
systemic exposure cannot be achieved with standard formulations, it is inevitable to identify viable 
candidate-enabling formulation strategies, preferably at an early stage where very limited amounts 
of material is available. Recently, besides physico-chemical characterization, formulation screening 
in high-throughput format has gained attention to streamline the costly and challenging process 
of formulation design. Due to the increasing fraction of NCEs with challenging physico-chemical 
properties, the demand for simple, rapid, yet effective formulation screening tools has increased in 
recent years. In particular, poor aqueous solubility is a frequently experienced challenge that has 
resulted in the widespread use of candidate-enabling formulation strategies with the aim to increase
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the oral bioavailability of poorly soluble drug compounds. Micro- and nanoparticles, amorphous 
solid dispersions (ASDs) and lipid-based formulations are only few examples of the many 'enabling 
formulation' strategies available today [1] .
Miniaturized solubility screening tools have been commonly used in early development to help 
select suitable solid forms and salts of the drug [2,3]. In recent years, high-throughput screening (HTS) 
of formulation additives, such as polymer(s), polymer/surfactant combinations and drug loading, 
of amorphous solid dispersions (ASDs) has also been suggested [4]. High-throughput ASD screenings 
can be carried out in 96-well microplate set-ups and typically investigate the miniaturized formulations' 
potential to induce supersaturation (often referred to as 'spring') and to inhibit precipitation (often 
referred to as 'parachute').
Traditionally, supersaturation screenings employ solvent shift or film casting. Solvent shift 
methods evaluate, besides the so-called kinetic solubility, precipitation inhibition in the presence of 
additives. Here, a drug compound is dissolved in a suitable solvent at a high concentration and is then 
titrated into aqueous media to induce supersaturation. The aqueous medium contains excipient(s) 
that may inhibit the precipitation due to the solvent shift [5- 7]. For solvent casting, drug compound, 
polymer and eventually surfactant solutions are prepared using a suitable volatile organic solvent, 
the solutions are dispensed in various combinations and/or ratios followed by solvent evaporation 
to form films. The film s' solid-state and/or solubility and dissolution behavior are analyzed and 
serve as surrogates to predict ASD performance [4,8- 10]. Banda et al. (2017) reported a head-to-head 
comparison of the two screening methods using up-scaled spray-dried ASDs for verification and 
summarized advantages and drawbacks of both methods [11].
Recently, Auch and co-workers presented a melt-based screening method. Here, a melting-step 
was added after preparation of the solvent-casted drug/polymer films to closer mimic the conditions of 
hot-melt extrusion [12].
Alternatives for small-scale preparation of drug/polymer films include rapid solvent evaporation 
using spin-coating and 2D-inkjet printing, where polarized light microscopy is used to evaluate the 
solid-state of the films [13,14]. Films prepared by these alternative methods can only be ranked 
according to their solid-state and stability upon storage. Supersaturation/precipitation kinetics in an 
aqueous environment are, however, difficult to predict from solid-state and stability data.
The HTS methods described above and further high-throughput formulation screenings described 
in literature so far have in common that they use the 'dissolved' amount of drug compound as primary 
parameter to predict the performance of the formulation. In these pharmaceutical assessments, different 
'dissolved' states of the drug compound are typically not distinguished. Different 'dissolved' states (i.e., 
drug molecules that are 'molecularly' dissolved, drug molecules that are solubilized in micelles or other 
supra-molecular assemblies and/or drug molecules that are complexed (e.g., cyclodextrin)) may occur 
due to formulation excipients and/or constituents of (biomimetic) media. These different 'dissolved' 
states may have different chemical potentials and therefore may have different impacts on formulation 
performance [15- 19]. Because of this, Buckley and co-workers already in 2013 argued that a change of 
paradigm in biopharmaceutical evaluation of enabling formulations is needed [20]. A recent review 
and meta-analysis on supersaturating drug delivery systems indicated the widespread failure in 
predicting in vivo performance from in vitro supersaturation data [21]. It has been demonstrated that 
by including an absorptive compartment when investigating supersaturation/precipitation kinetics, 
a better formulation evaluation regarding in vivo properties can be achieved [19,22- 25]. Here, removal 
of dissolved drug compound from the dissolution vessel decreases the degree of supersaturation, 
thereby decreasing the likelihood of precipitation and thus retaining the supersaturated state for a 
longer period.
In this work, we report a high-throughput dissolution/permeation approach for formulation 
screening that for the first time uses a 96-well two-compartment microplate system consisting of a 
conventional bottom-plate and a top-plate comprising an integrated dialysis membrane (cellulose 
hydrate). Figure 1 shows a schematic representation of the two-compartment microtiter plate system.
Pharmaceutics 2019,11, 227 3 of 15
This set-up was presumed to potentially solve both aforementioned challenges; differentiation between 
the permeation enhancing potential of molecularly dissolved and solubilized states of the drug and 
formulation rcreening in the presence of an absorptive compartment in miceo-scale.
Figure 1. A schematic representation of the 96-well two-compartment microtiter plate.
This study aimed to establish a high-throughput dissolution/permeation approach and to 
investigate its feasibility, practicability find predictive potential. For thio purpose, formulations 
of tire poorly soluble BCS class II drug tadalafil (TDF) were used as an example [26]. In centrast to [26], 
where ball milling was used, we employed freeze drying to prepare the amorphous formulations . 
Freeze drying resembles solvent casting yet has a minimized risk of re-crystallisation . tn Fhis sUudy, 
various high-throughput dissolution/permeation experiments were conducted to investigate how 
different screening parameters (i.e., incubation time, dispersion media, and acceptor media) influence 
the practicability and predictability of the screening.
2. Materials and Methods
2.1. Chemicals
Acetonitrile (HPLC-grade), formic acid, polysorbate 80 (PS 80), sodium chloride, sodium 
dihydrogen phosphate monohydrate, sodium hydrogen phosphate (anhydrous), sodium dodecyl 
sul'ate (SDS ) and tert-butanol were purc hased from Sigma-Aldrich® De nmark ApS (Brondby, D enmark) . 
Sodium hydroxide was jeurcltosed from Merck AOS (Hellerup, Denmarlr). Soluplus®, an amphiphilic 
graft co-polymer based on polyethylene glycol, polyvinyl caprolactem and polyvinyl acetate, was 
kindly donated by BASF SE (Ludwigshafen, Germany). Tadalafil (TDF; purity 99%) wao purchased 
from abcr GmbH (Karlsruhe, Germany). D-coTocopher^ polyethylene glycol 1000 sucrinate (Vitamin 
E TPGS) ONF grade) was kindly donated by Gustrv Parmentier d mbH (Frankfurt am Main, Germany) . 
If not sleted otherwise, chemicals were of analytical grade. Simulated intestinal fluid (SIF) instant 
powder containing sodium taurochFfate and lecithin was purchased from biorelevaat.com (London, 
United Kingdom). Highly purified water used fot the preparation of all dispersion- and acceptor 
media and aqueous UHPLC solvent was freshly prepared using a Milli-Q® integral weter purification 
system (Milli-Q® Advantage A10®; Merck Millipore, M eick APS, Hellerup, Denmark).
2.2. Methods
2.2.1. Preparation of Dispersion Media and Acceptor Media
In this study, three media for dispersing the tadalafil formulations were evaluated, a 50 mM 
phosphate buffer, simulated gastric fluid (SGF) and fasted state simulated intestinal fluid (FaSSIF). 
To prepare the 5k mM phoephate buffer 1.156 glL s odium d ihydrogen phosphate monohydra(e and 
5.54 g/L sodium hydrogen phosphate (anhydrous) were dissolved in purified water (approximhlely 
9d%o of the final volume), pH adlueted to 7.4 with t  M NaOH knd mado up io the final volume. SGF 
was prepared rccording to Ph. Eur. 9).8 monograah (5.17.1. 'Recommendations on dissolotion testing;'). 
Briefly, sodium chloride was dissolved in purified water and the pH was adjusted to 1.d using 1 M 
HCl . Phosphate buffered saline ('FaSSIF blank buffer') pH 6.5 and FaSSIF were prepared according to 
'How to make FaSSIF/UeSSIF/FaSSGF' (biorelevant. com 2018). FaSSIF was prepare d one day before the
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high-throughput dissolution/permeation screening by dispersing FaSSIF instant powder in 'FaSSIF 
blank buffer'.
In this study, five acceptor media were evaluated: neat phosphate buffer and four surfactant 
solutions, 1% (w/v) SDS, 0.2 and 1% (w/v) Vitamin E TPGS, and 0.2 and 1% (w/v) PS 80 in phosphate 
buffer. Furthermore, 1% (w/v) Vitamin E TPGS solution in SGF or 'FaSSIF blank buffer' was prepared. 
All surfactant solutions had a concentration well above the respective surfactants' critical micelle 
concentration. The surfactant solutions were prepared by dispersing the surfactant in the media 
followed by sonication at room temperature (RT) for 15 min or until a clear solution was obtained.
All dispersion- and acceptor media were stored at 4 to 8 °C for up to three months.
2.2.2. Solubilization of Tadalafil in Surfactant Solutions
The solubilization of tadalafil in surfactant solutions was investigated by dispersing 4 mg tadalafil 
in 4 mL surfactant solution in phosphate buffer (see above). As control, 4 mg tadalafil was dispersed in 
neat phosphate buffer. The dispersions were shaken at 300 rpm using an orbital shaker. After 24 h, solid 
material was distinctively visible in all vials. Samples were withdrawn, transferred to micro-centrifuge 
tubes and centrifuged for 60 min at 14,000 rpm (19,500x g) and 25 °C using an Eppendorf Centrifuge 
5804 R (Eppendorf AG, Hamburg, Germany). For quantification by UHPLC-UV, the supernatant was 
diluted 1:20 with a 1:1 mixture of acetonitrile and phosphate buffer.
2.2.3. Preparation of Tadalafil Formulations and Their Aqueous Dispersions for High-Throughput 
Dissolution/Permeation Screening
Two tadalafil formulations were prepared by freeze drying, namely pure amorphous tadalafil 
and a 1:9 tadalafil amorphous solid dispersion (ASD) in Soluplus®. To prepare the formulations, 
tadalafil and Soluplus® were dissolved in 4:1 (w:w) tert-butanol:water-mixture (tadalafil concentration 
1.3 mg/mL, Soluplus® concentration 3.5 mg/mL), aliquots of the solutions were transferred to 1.5 mL 
microcentrifuge tubes and the formulations were frozen over night at -8 0  °C. The Christ Gamma 2-16 
LSC freeze-dryer (Martin Christ GmbH, Osterode am Harz, Germany) was pre-cooled to -6 0  °C and 
freeze drying was conducted at a pressure of 0.1 mbar and a shelf-temperature of 10 °C for 25 h. The 
freeze-dried formulations were placed in a desiccator over CaCO3 beads to reach room temperature. 
The high-throughput dissolution/permeation screening was conducted one day after formulation 
preparation. For this, 1.5 mL of the respective dispersion media was added, and the formulations were 
vortexed until homogenously dispersed.
For comparison, suspensions of crystalline tadalafil and of a physical blend of tadalafil and 
Soluplus® (further on termed 'physical mixture') were prepared. For this, tadalafil and a mixture 
of tadalafil and Soluplus® were dispersed in the respective dispersion media. The tadalafil 
suspension and the physical mixture were stirred for 15 min at 500 rpm prior to the high-throughput 
dissolution/permeation experiment. Table 1 shows an overview of all prepared formulations and the 
concentrations of tadalafil and Soluplus® in the dispersions.
Table 1. Overview of tadalafil formulations/dispersions used in the high-throughput 
formulation screening.
Formulation Tadalafil Concentration in Dispersion (mg/mL)
Soluplus® Concentration in 
Dispersion (mg/mL)
Crystalline TDF 0.1
Freeze-dried TDF 0.1
Physical mixture 0.1 0.9
Amorphous solid dispersion 0.1 0.9
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2.2.4. X-Ray Powder IDiffraction
The solid state of tadalafil, Soluplus®, freeze-dried tadalafil and the tadalafil amorphous solid 
dispersion was investigated by X-ray powder diffraction (XRPD) using a Rigaku®, MiniFlex 600 with 
Cu K a  radiation (l =  1.541.8 A) (Tokyo, Japan). For f:lnis, freeze-dried tadaHfil and tadalafil amorphous 
solid dispersion were prepared in larger batches to fill the sample holder with a diameter of 2 cm. The 
up-scaled batches were prepared ae described in Section 2.2.3. with slight modifieations: a 16 mg/mL 
Soluplus® solution was used and tadalafil and the amorphous solid dirpersion were freeze dried in 
100 and 30 mL -vials, respectively. The XRPD analysis was carried out wifh a scanning rate i f  .  °/min in 
20, a step width of 0.02° over the range of 5-35°. The current was 10 mA and the voltage 30 kV.
2.2.5. High-Throughput DissolutionnPermeation Screening
Figure 2 shows a flow-diagram of the complete high-throughput dissolution/permeation 
screening procedure including preparation of the formulation, where applicable (See Section 2.2.3), 
the dissolution/permeation experimen/s (described in this section) and the quantification of tadalafil 
(See Section 2.2.7).
Figure 2. A flow-diagiam of the high-throughput dissolution/permeation srreening. Stcp0. Formulation 
preparation, Step 1. Dispersion of the formulations, .tep 2. Incubation erf the two-compartment plate,
Step 3. Sampling from the top-plate (a ccrptor) and bottom-plaPe (donor) arid Step 4. QTantification of 
tad altfii by UHPLC.
Table 2 gives an overview of all the formulations that were tested for high-throughput 
dissolution/permeation. in more detail, Table 2 gives an overview nt the parameters under which the 
formulations were tested to evaluate the influence of acceptor media, incubation time and dispersion 
media, as well as to evaluate predictiveness of the screening by comparison to oral bioavailability data.
"[’able 2. Overview of all conducted high-throughput dissolution/permeation experiments to evaluate 
the influence of experimental parameters: (1) acceptor medium; (2) incubation time; and (3) 
dispersion medium.
Experimental 
Parameter to be 
Evaluated
Formulations DispersionMedia Acceptor Medea
Incubation
Time
Number of 
Experiments
Acceptor medium Crystalline tadalafil (TDF)
50 mM phosphate buffer
1% sodi um dodecyl sulfate 
(SDS) in phosphate buffer
50 mM 0.2% Vitamin E T/GS in
phosphate phosphaie buffer__________
buffer 1% Vitamin E TPGS in
phosphaie buffer
0.2% PS 80 in phosphate buffer
24 h 6
1% PS 80 in phosphate buffer
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Table 2. Cont.
Experimental 
Parameter to be 
Evaluated
Formulations DispersionMedia Acceptor Media
Incubation
Time
Number of 
Experiments
Crystalline TDF 1h
Freeze-dried TDF 50 mM 1% Vitamin E TPGS in 3 hIncubation time Physical mixture phosphate phosphate buffer
6 h
12
Amorphous solid 
dispersion
Crystalline TDF
50 mM
phosphate
buffer
1% Vitamin E TPGS in 
phosphate buffer
Dispersion medium Freeze-dried TDF
Simulated 
gastric fluid
(SGF)
1% Vitamin E TPGS in SGF 6 h 12
Physical mixture 1% Vitamin E TPGS in FaSSIF
Amorphous solid FaSSIF
dispersion
The screening experiments were conducted in prototypes of a novel two-compartment microtiter 
plate system, which were kindly provided by InnoMe GmbH (Espelkamp, Germany). The top-plate of 
the microtiter plate system comprised an integrated dialysis membrane consisting of cellulose hydrate. 
The screening experiments were conducted according to the following general procedure: 300 pL 
of the freshly dispersed formulations were transferred to the bottom-plate (n =  3-6) and 200 pL of 
acceptor medium (surfactant solution or phosphate buffer) was placed in the top-wells of the plate. 
The top-plate was sealed with pierceable, adhesive sealing foil (x-Pierce™, Excel Scientific, Inc.) and 
closed with the corresponding lid. The set was incubated at room temperature under shaking (300 rpm) 
with an orbital shaker. During the incubation, tadalafil permeated from the bottom-wells (i.e., donor 
compartment), to the top-wells (i.e., acceptor compartment). After either 1, 3 or 6 h of incubation, 
samples were withdrawn from both, the donor and the acceptor compartments. The samples from the 
acceptor compartments (140 pL) were diluted 1:1 with acetonitrile for UHPLC-UV analysis. To separate 
the dissolved drug from the non-dissolved solid material, the samples from the donor compartments 
(complete well volume) were transferred to micro-centrifuge tubes and centrifuged for 60 min at 
14,000 rpm (19,500x g) and 25 °C using an Eppendorf Centrifuge 5804 R (Eppendorf AG, Hamburg, 
Germany). The supernatant was diluted 1:1 with acetonitrile for UHPLC-UV analysis. Quantification of 
tadalafil was then conducted via UHPLC-UV as described in Section 2.2.7. The tadalafil concentration 
in the donor- and acceptor compartment, that is, the dissolved and permeated concentrations, were 
used to compare the screening parameters and to establish an in vitro in vivo correlation. The in vitro 
in vivo correlation was established by comparing to literature data [26].
2.2.6. Non-Specific Adsorption of Tadalafil to Plastic Material
The loss of a drug compound due to non-specific adsorption to plastic material may represent a 
problem. To investigate if tadalafil adsorbs to the plastic material of the two-compartment microtiter 
plate a 0.9 pg/mL tadalafil solution in purified water was prepared, which is well below the aqueous 
solubility of tadalafil (~2 pg/mL). The tadalafil solution was transferred to the bottom-plate of the 
two-compartment microtiter plate system and incubated. The tadalafil concentration was determined 
after 3, 6 and 24 h of incubation as described in Section 2.2.7. using UHPLC-UV and compared to the 
start concentration.
2.2.7. Quantification of Tadalafil by UHPLC-UV
Quantification of tadalafil was conducted on a Thermo Fisher UltiMate 3000 UHPLC system that 
was connected to a Diode Array detector and equipped with a reversed phase Kinetex® EVO C18
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LC-column (100 X 2.1 mm; particle size 1.7 pm; pore size 100 A, Phenomenex®). The flow rate was 
0.3 mL/min and the mobile phase consisted of 57% (v/v) highly purified water containing 0.1% (v/v) 
formic acid as modifier and 43% (v/v) acetonitrile (isocratic elution). The column oven temperature 
was set to 40 °C. The total run time was 3 min, where tadalafil eluted after 1.5 min. tadalafil was
detected at a wavelength of 295 nm. Two standard curves were prepared with concentration ranges of 
0.1-2 pg/mL and 2-20 pg/mL, respectively. The injection volume was 5 pL.
2.2.8. Statistical Analysis
Statistical analysis was performed using a one-way ANOVA test to identify statistical significance 
within groups of data sets and a two-tailed, unpaired Student's t-test to compare two data sets. For both 
tests, p <  0.05 was considered as statistically significant.
3. Results and Discussion
3.1. Sam plePreparationand Solid-State Analysis byX -Ray Powder Diffraction
Krupa et al. (2016) proposed high-energy ball milling ass a process to obtain amorphous tadalafil 
and amorphous solid dispersions of tadalafil in Soluplus® by co-milling [22]. High-throughput 
formulation screening applications require a simple formulation preparation method, by which 
formulations with different excipients, excipients combinations and/or excipient ralios can tie prepared, 
preferably in a single; run. Classical (co-)milling does not eseet these criteria because only one 
formulatipn can be prepared per run. We used freeze-drying from hydro-alcoholic solutions as a 
simple and rapid procoss to obtain (amorphous) tadalafil fo rmulations for sc reening applicatiano.
In the diffractograms shown in Figure 3, the tadalaffl-crystal specific pattern is absent in the 
freeze-dried samples (tadalafil alone and co-freeze dried tadalafil with Soluplus®). This indicates that 
these samples are amorphous and that freeze-drying from hydro-alcoholic solutions is a viable option 
to obtainamorphous formulations for screening applications.
Figure 3. X-ray diffraction patterns of all formulations, tadalaffl and Soluplus®.
3.2. Non-Specific Adsorption o f  Tadalafil to Plastic Maaeeial
Non-specific adsorption of drug; compounds to plastic material can be detrimental for 
biopharmaceutical assessments. This is commonly investigated by incubating a solution of ihe 
doug compound ip the preoence c f the material. A  decrease in drug) compound concentration is
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Figure 4. Non-specific adsorption of tadalafil to the plastic material of tire two-compartment microplate 
system shown as the tadalafil concentration in tire bottom-well after 3, 6 and 24 h incubation of a 
0.9 ggtmL tadalafil solution. '0 h' indicates the 'unincubated' (start) concentration. Data shown as 
mean ± SD ot six replicates.
3.3. Preliminary Experiments—Incubation 'Time, Acceptor Media and Dispersion Media
3.3.1. The Influence of Acceptor Media
In Figure 5 the solubilization effect of different surfactant solutions on tadalafil solubility is 
compared fo the tadalafil permeation when using these surfactant solutions as acceptor media. 
The dissoluiion/permeation experiment was conducted using a suspension of crystalline tadalafil as 
donor. In both studies neat phosphate buffer served as a control, and incubation time was 24 h.
All surfactaat solutions solobilized tadalafil as indicated by a significant increase in tadalafil 
concentration compared to neai phosphate buffer (see Figure 5A). When using these surfactant solutions 
as acceptor media, the permeated amount of tadalafil was increased significantly in all cases (see 
Figure 5B). Tadalafil solubilization arid permeation enhancemeni seem to follow a similar pattern, 
where the highest solubilization leads to the fasOest permeation. However, the differences in terms of 
solubflization are far more pronounted than the differences in permeation rate.
s% SDS yielded both the highest tadalafil solubilization and fasiest pesmestion. When comparing 
the effectiveness of the other surfactant solutions;, Vitamin E TPGS and PS 80, no significant difference 
in teoms of permeation was found between the two turfactant solutions w.th the same concentrations 
(0.2%o or a°%o), even though a significant difference was seen in aolubilization capatity. Still, a surfactant 
concentration of 10% compaeed to 0.2% was suparior ia  both cases, which is also reflected in the 
solubilization capacity.
In general, the results indicate that using surfactant solution as acceptor medium is beneficial for 
the high-throughput dissolution/permeatian screening; by enhancing tht permeation of poorly soluble
regarded to indicate adsorption to the material. Figure 4 shows the tadalafil concentration in the 
bottom-wells when incubating a 0.9 gg/mL tadalafil solution. After 3 h of incubation, the tadalafil 
concentration is decreased by approximately 12% indicating minor adsorption to the plastic material. 
After 6 and 24 h of incubation, the tadalafil concentration increased slightly, likely due to solvent 
evaporation. Even though precautions are taken (e.g., by using sealing films), evaporation from 
microtiter plates is often observed due to their large surface area. The minor non-specific adsorption 
was regarded negligible for the further dissolution/permeation screenings.
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drug compounds. The permeation enhancing effect can be explained by at least two factors. Firstly, 
the surfactant solutions decrease adsorption to the plastic material. Secondly, the surfactants solubilize 
the drug compound in the acceptor compartment thereby maintaining/increasing the driving force for 
permeation. In essence, both factors result from increasing the drug compounds affinity towards the 
acceptor medium.
Due to analytical challenges observed with samples containing 1% SDS (i.e., chromatograms with 
poor peak shape), 1% Vitamin E TPGS solution was used as acceptor medium in further high-throughput 
dissolution/permeation experiments.
Figure 5. Comparison of (A) the apparent solubility of tadalafil in different surfactant solutions with 
(B) the tadalafil concentration in the acceptor compartment when using the different surfactant solutions 
as acceptor media. In all cases the donor was a suspension of crystalline tadalafil in phosphate buffer.
Both (A) and (B) were determined after 24 h of incubation. Data shown as mean ± SD of triplicates.
3.3.2. The Influence of Incubation Time
Figure 6 gives the tadalafil concentration in the donor compartment (Figure 6A ) and acceptor 
compartment (Figure 6Bf after 1t 3 and (5 lo of incubation. Here, tadalafil dormulations were dispersed 
in photphade buffer.
As can be seen in Figure 6A, the four formulations induced different concentrations of apparently 
dissolved tadalafil. Focusing on the influence of incubation time in this section, this effect will be 
discussed in detail below (see Sections 3.3.3 and 3.4). The differend incubation times appeared So 
have marginal influence on thf concentra)ion of dissolved tadalafil (see Figure 6A). However, for the 
crystalline samples, a very slight inerease tn the dissolved ladalafil concentration from 1 h to 3 It was 
observed. This indicates that saiuration solubility is almost reached a)tes one hour in these cases. 
Interestingly, no change in dissolved tadalafil concentration err even a minor decrease was siren with 
the amorphous s amples: after one hour the am orphous tadalafil (freez e-dried TDF) showed the leighert 
this solved tadalafil concentration with a  tendency to lower -values after 3 and 6. Is of incubation. This 
can be an indication for initial suaersaturation with subsequent precipitation. Due to lack of solid-state 
data on the precipitate, it is difficult to judge whether a precipitation in amorphous or crystalline form 
occurred here. For the amorphous solid dispersion high and quite conttant concentrations of dissolved 
tadalafil were obsesved, which is regarded indicative ior both high and long-lasting supersaturation 
and effltient micellar solubilization of tadalafil by Soluplus® over the whole range of incubation times.
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The tadalafil concentration in the acceptor compartment (i.e., the permeated tadalafil) differed 
significantly between the four formulations (see Figure 6B). This effect will be discussed in more detail 
below (see Sections 3.3.3 and 3.4).
The differences between the four formulations were reflected at all three incubation times. Still, 
one should consider that the values after one hour were just slightly above the limit of quantitation 
of the analytical method (data not shown); later time points appeared thus better suited to reveal 
differences between the formulations in a significant manner.
Figure 6. Tadalafil concentration in (A) the donor compartment and (B) the acceptor compartment after 
1, 3 and 6 h of incubation when using; different tadalafil formulations dispersed in 50 mM phosphate 
buffer as donor. The acceptor medium was 1% "Vitamin E TPG S in 50 mM phosphate buffer. Data shown 
as mean ± SD of four replicates.
3.3.3. The influence of Dispersion Media
To evaluate the influence of different dissolution media on the high-throughput 
dissolution/permeation screening, the tadalafil formulations were dispersed in either phosphate 
buffer, SGF, or FaSSIF. In this screening, 1% Vitamin E TPGS dissolved in the respective medium (i.e., 
phosphate buffer, SGF or ' FaSSIF blanO b uffer') -was used as the ac ceptor medium. Figure 7 shows the 
results from this screening test.
Figure 7A shows the tadalafil concentration in the donor compartment after six hours of incubation. 
For all formulations, the ranking of tadalafil concentrations in the donor compartment was FaSSIF >  
SGF >  phosphate buffer. FTere, the difference between phosphate buffer and SGI1 was not pronounced, 
whereas the tadalafil concentration in FaSSIF was approximaPely doublrd (as rompared to SGF or 
phosphate buffer) due to the solubilizing components, sodium taurocholate and lecithin, that are 
contained in this media.
Krupa and co-workers conducted a dissolution study on similar (ball-milled) formulations using 
a paddle dissolution apparatus [26]. In this study, 500 mL of SGF (pH 1.2) or phosphate buffer (pH 7.4) 
were used as dissolution medium. After 6 h, approximately 3 ,4 .5 ,16 .6  and 24 pg/mL were reached in 
SGF for the dissolution of crystalline tadalafil, amorphous tadalafil, physical mixture and amorphous 
solid dispersion, respectively. In phosphate buffer, approximately 3 ,4 ,4 .7  and 21 pg/mL were reached 
after 6 h for the same formulations.
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Figure 7. Tadalafil concentration in (A) the donor compartment or (B) the acceptor compartment after 
6 h of incubation using different media for dispersion of the formulations. The acceptor medium was 
1% Vitamin E TPGS in the respective dispersion medium. Data shown as mean ± SD of four replicates.
Compared to the large-scale dissolution method, the high-throughput dissolution/permeation 
method generally yielded a similar outcome in terms of dissolved tadalafil, that is, higher tadalafil 
concentrations in SGF as compared to phosphate buffer, higher tadalafil concentrations from amorphous 
tadalafil as compared to crystalline tadalafil, superior tadalafil concentrations from the amorphous 
solid dispersion as compared to all other formulations.
Still, the high-throughput dissolution/permeation screening did not reflect all aspects of the 
large-scale dissolution study. In SGF, Soluplus® positively affected the dissolution of crystalline 
tadalafil, that is, the tadalafil concentration of the physical mixture was approximately increased 4-fold 
in SGF compared to phosphate buffer, and even came close to that of the amorphous solid dispersion. 
The high-throughput screening results did not reflect this. Insufficient stirring of the viscous polymer 
solution and/or the slightly higher pH of the media (1.2 vs. 1.3) may explain this. However, in vivo 
oral bioavailability data from the same study did not reveal such a tremendous positive effect of 
Soluplus® on the bioavailability of crystalline tadalafil [26]. This will be discussed in more detail below 
(see Section 3.4).
Furthermore, the high-throughput screening yielded lower absolute tadalafil concentrations 
compared to the large-scale dissolution study likely due to the temperature difference between 
the experiments. The high-throughput screening was conducted at room temperature (<25 °C), 
whereas the dissolution study was conducted at 37 °C. To increase biorelevance, the high-throughput 
dissolution/permeation can be conducted at 37 °C instead of 25 °C. However, increased evaporation 
can be a limiting factor at higher temperatures.
Figure 7B shows the tadalafil concentration in the acceptor compartment after six hours of 
incubation. In contrast to the tadalafil concentration in the donor compartment (see Figure 7B), 
the different dispersion media did not affect the tadalafil concentration in the acceptor compartment 
noticeably. Only for the freeze-dried tadalafil a significant difference was observed. In this case, 
the presence of FaSSIF significantly increased the permeation as compared to both phosphate buffer 
and SGF.
In a previous dissolution/permeation study on solid phospholipid dispersions of celecoxib, 
a similar effect was observed where the presence of FaSSIF promoted the permeation of freeze-dried 
celecoxib [27]. Upon freeze-drying, the crystalline tadalafil was amorphized as shown in the XRPD 
analysis (see Section 3.1) . In contact with aqueous media, rapid recrystallization and precipitation of 
freeze-dried tadalafil may be expected due to the inherent thermodynamic instability of amorphous 
systems. However, data from this study on tadalafil and the previous study on celecoxib suggest that
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FaSSIF may retard/reduce precipitation from these very unstable amorphous systems. Precipitation 
inhibition is a plausible mechanistic background for the enhanced permeation of freeze-dried tadalafil 
because the presence of FaSSIF did not noticeably affect the permeation of crystalline tadalafil and the 
physical mixture of tadalafil with Soluplus®. The precipitation inhibiting effect of FaSSIF is, however, 
only evident in the absence of other precipitation inhibitors (e.g., polymers). Namely in the case of the 
amorphous solid dispersion, the presence of FaSSIF did not enhance tadalafil permeation compared to 
phosphate buffer and SGF.
Other studies investigated the effect of simulated intestinal fluids and human intestinal fluids on 
supersaturation [28- 30]. These studies relied on determining the dissolved amount via conventional 
separation techniques (i.e., centrifugation and/or filtration). Separation is a complex and tedious 
process that is prone to sampling complications (i.e., filter pore-size and centrifugation parameters can 
affect the amount of drug defined as dissolved). Investigating supersaturation based on the amount of 
drug permeated across a dialysis membrane, as presented here, can be an attractive alternative to the 
conventional separation approach.
Furthermore, extent and duration of supersaturation, when tested under absorptive sink conditions, 
may exceed that observed under static conditions [31].
3.4. In Vitro In Vivo Correlation: Comparing the In Vitro High-Throughput Dissolution/Permeation Screening 
Results to In Vivo Oral Bioavailability Results
The previous section focused on practical aspects of the high-throughput dissolution/permeation 
screening. This section will discuss the results of the high-throughput dissolution/permeation screening 
from a prediction perspective by comparing them to oral in vivo bioavailability data from [26].
The in vivo study in rats conducted by Krupa and co-workers on similar tadalafil formulations 
prepared by ball-milling showed that the absorption of tadalafil was significantly increased from the 
amorphous solid dispersion containing Soluplus® [26]. In both aspects, dissolution and permeation, 
the high-throughput screening could reflect the superiority of the amorphous solid dispersion over 
the other formulations (See Figure 7). For an amorphous formulation that is not 'stabilized' by a 
precipitation inhibitor (e.g., a polymer), the amorphous tadalafil (ball-milled tadalafil) performed 
surprisingly well in the in vivo study. Ball-milled, amorphous tadalafil yielded the second highest 
AUC in the in vivo study. This was not reflected very well in the dissolution experiment conducted 
by Krupa and co-workers where the physical mixture of tadalafil was either superior to amorphous 
tadalafil (in SGF) or comparable to amorphous tadalafil (in phosphate buffer pH 7.4). The observed 
difference between in vitro dissolution and in vivo absorption is likely due to the more pronounced 
propensity of molecularly dissolved vs. micellarly solubilized drug to promote transport across an 
absorptive barrier. The high-throughput dissolution/permeation screening, however, was able to reflect 
this in certain aspects of the screening.
Table 3 gives the coefficient of determination when plotting the dissolved tadalafil concentration 
or the permeated tadalafil concentration (i.e., the tadalafil concentration in the donor or acceptor 
compartment) after 6 h of incubation against the in vivo AUC. Table 3 summarizes experiments where 
different dispersion media were used. Generally, for both the dissolved and the permeated tadalafil 
concentration, a good correlation between the in vivo and the in vitro results was achieved.
Table 3. Coefficient of determination when plotting the dissolved tadalafil concentration or the 
permeated tadalafil concentration (i.e., concentration in donor or acceptor compartment) for experiments 
using different dispersion media after 6 h of incubation against in vivo AUC from [26].
Dispersion Medium R2 (Dissolved Concentration vs. AUC) R2 (Permeated Concentration vs. AUC)
50 mM Phosphate buffer 0.846 0.850
SGF 0.826 0.864
FaSSIF 0.823 0.940
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Yet when SGF or FaSSIF was used as dispersion medium, the permeated tadalafil concentration 
correlated better with the in vivo AUC than the dissolved tadalafil concentration. For all experiments, 
the permeated tadalafil concentration where FaSSIF was used as dispersion medium yielded the 
best correlation. In these aspects of the screening, the surprisingly good performance of the 
amorphous tadalafil was reflected best. As discussed in Section 3.3.3, the presence of FaSSIF 
significantly increased tadalafil permeation from the pure amorphous formulation as compared 
to SGF and phosphate buffer. Experiments using SGF or phosphate buffer as dispersion medium 
underestimated the performance of amorphous tadalafil. Figure 8 gives an overview of the results 
from the high-throughput dissolution/permeation screening experiment where FaSSIF was used as 
dispersion medium. For comparison, the in vivo AUC's from literature are given in Figure 8.
Figure 8. Tadalafil concentration in (A) the donor compartment (dissolved) or (B) tire acceptor 
compartment (permeated) and ((F) in vivo AUC rfter oral gavage to rats taken from [26].
The in vitro 'absorption' of tadalafil, that is, the amount of tadalafil reaching the acceptor 
compartment from the tadalafil available in the donor compartment, was relatively low as compared 
to the ita vivo situation. For the best performing formulation, approximately 4% of available tadalafil 
was transported to the acceptor compartment. In this study, surfoctant solutions were used to ensure 
sink conditions and thereby maintain a high driving-force for tadalafil permeation.
4. Conclusions
In tins study a novel approach was estebfished that allows us to simultaneously investigate 
the dissolution (release) of a drug and its transfer across an artificial barrier over time. For this 
approach, a prototype 96-well titer plate with an integrated dialysis membrane separating two 
micro-compartments withon each well was used . For evaluation erf the approach, the model drug 
tadalafil was employed both in amorphous and crystalline state, alone and in combination with 
Soluplui® (physical mixture and am orphoub solid dispersion). In situ amorphization was accomplished 
by dissolution in r-butanol/water, freezing and freeza-dryang.
lilie concentrations of dissoOved and permeated tadalafil correlated reasonabty 'well with rat 
bioavafiability reported in literature. A better ranking was ieen for the permeated, as compared to 
the dissolved, amounts. Here, tire good in vivo performance of pure amorphous tadalafil was best 
reflected. The set-up is supposed to catch the different impact that supersaturation and micellar 
solubilization (by the amphiphific Soluplus®) have on apparent solubility and permeability.
Among the experimental parameters tested, FaSSIF as donor medium, 1% Vitemin E TPGS as 
acceptor medium and sampling after six hours appeared to lie superior in terms of practicability and 
predirtiveness for ihe formulations investigated here.
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While the approach appears promising for early-stage high-throughput formulation performance 
ranking, a general conclusion regarding its predictivity, also in comparison to existing approaches, 
will need further evaluation, employing additional drug compounds and formulations.
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